Non-HFE hemochromatosis;Hemocromatosis no ligada al HFE

Revista Espanola de Enfermedades Digestivas

Volumn 97, Issue 4, 2005, Pages 266-286

  Solis Herruzo J A ^a   Solis Munoz P ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HFE PROTEIN;

DISEASE CLASSIFICATION; GENE MUTATION; GENETIC DISORDER; HEMOCHROMATOSIS; HUMAN; IRON DEFICIENCY; IRON OVERLOAD; REVIEW;

EID: 19944406154     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: 10.4321/S1130-01082005000400007     Document Type: Review

References (158)

1. von Reckinghausen FD. Über Hämochromatose. Tagesblatt Versammlung deutsche Naturforscher Ärzte Heidelberg 1888; 62: 324-5.
2. Simon M, Le Mignon L, Fauchet R, Yaouanq J, David V, Edan G, et al. A study of 609 HLA haplotypes marking for the hemochromatosis gene. Am J Hum Genet 1987; 41: 89-105.
3. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13: 399-408.
4. Merryweather-Clarke AT, Pointon JP, Jouanolle AM, Rochette J, Robson KJH. Geography of HFE C282Y and H63D mutations. Genet Test 2000; 4: 183-98.
5. Murphy S, Curran MD, McDougall N, Callender ME, O'Brien CJ, Middleton D. High incidence of the Cys 282 Tyr mutation in the HFE gene in the Irish population - implications for haemochromatosis. Tissue Antigens 1998; 52: 484-8.
6. Steinberg KK, Cogswell ME, Chang JC, Caudill SP, McQuillan GM, Bowman BA, et al. Prevalence of C282Y and H63D mutations in the hemochromatosis (HFE) gene in the United Status. JAMA 2001; 285: 2216-22.
7. Papanikolaou G, Politou M, Terpos E, Fourlemadis S, Sakellaropoulos N, Loukopoulos D. Hereditary hemochromatosis: HFE mutation analysis in Greeks reveals genetic heterogeneity. Blood Cells Mol Dis 2000; 26: 163-8.
8. Milman N, Pedersen P. Evidence that the Cys282Tyr mutation of the HFE gene originated from a population in Southern Scandinavia and spread with the Vikings. Clin Genet 2003; 64: 36-47.
9. Bennet MJ, Lebron JA, Bjorkman PJ. Crystal structure of the haemochromatosis protein HFE complexed with transferrin receptor. Nature 2000; 403: 46-53.
10. Ehrlich R, Lemonnier FA. HFE: a novel nonclassic class I molecule that is involved in iron metabolism. Immunity 2000; 13: 585-8.
11. Riedel HD, Muckenthaler MU, Gehrke SG, Mohr I, Brennan K, Herrmann T, et al. HFE downregulates iron uptake from transferrin and induces iron-regulatory protein activity in stably transfected cells. Blood 1999; 94: 3915-21.
12. Corsi B, Levi S, Cozzi A, Corti A, Altimare D, Albertini A, et al. Overexpression of the hereditary hemochromatosis protein, HFE, in HeLa cells induces an iron-deficient phenotype. FEBS Lett 1999; 460: 149-52.
13. Roy CN, Penny DM, Feder JN, Enns CA. Hemochromatosis protein, HFE, specifically regulates transferrin-mediated iron uptake in HeLa cells. J Biol Chem 1999; 274: 9022-8.
14. Lebron JA, West AJ, Bjorkman PJ. The hemochromatosis protein HFE competes with transferrin for binding to the transferrin receptor. J Mol Biol 1999; 294: 239-45.
15. Waheed A, Grubb JH, Zhou XY, Tomatsu S, Fleming RE, Costaldi ME, et al. Regulation of transferrin-mediated iron uptake by HFE, the protein defective in hereditary hemochromatosis. Proc Natl Acad Sci. USA 2002; 99: 3117-22.
16. Ramalingam TS, West AP Jr, Lebron JA, Nangia JS, Hogan TH, Enns CA, et al. Binding to the transferrin receptors is required for endocitosis of HFE and regulation of iron homeostasis. Nature Cell Biol 2001; 2: 953-7.
17. Lebron JA, Bennet MJ, Vaughan DE, Chirino AJ, Show PM, Mintier GA, et al. Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor. Cell 1998; 93: 111-23.
18. Philpott CC. Molecular aspects of iron absorption: insight into the role of HFE in hemochromatosis. Hepatology 2002; 35: 993-1001.
19. Frazer DM, Anderson GJ. The orchestration of body iron intake: how and where do enterocytes receive their cues? Blood Cells Mol Dis 2003; 30: 288-97.
20. Bridle KR, Frazer DM, Wilkins SJ, Dixon JL, Purdie DM, Crawford DH, et al. Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homeostasis. Lancet 2003; 361: 669-73.
21. Hanson EH, Imperatore G, Burke W. HFE gene and hereditary hemochromatosis: a HuGE review. Am J Epidemiol 2001; 154: 193-200.
22. Risch N. Haemochromatosis, HFE, and genetic complexity. Nat Genet 1997; 17: 375-6.
23. Wallace DF, Walter AP, Pietrangel A, Clare M, Bomford AB, Dixon JL, et al. Frequency of the S65C mutation of HFE and iron overload in 309 subjects heterozygous for C282Y. J Hepatol 2002; 36: 474-9.
24. Barton EH, Sawada-Hirai R, Rothenberg BE, Acton RT. Two novel missense mutations of the HFE gene (I105T and G93R) and identification of the S65C mutation in Alabama hemochromatosis probands. Blood Cell Mol Dis 1999; 25: 147-55.
25. de Villiers JN, Hillermann R, Loubser L, Kotze MJ. Spectrum of mutations in the HFE gene implicated in haemochromatosis and porphyria. Hum Mol Gen 1999; 8: 1517-22.
26. Worwood M, Jackson HA, Feeney GP, Edwards C, Bowen DJ. A single tube heteroduplex PCR for the common HFE genotype. Blood 1999; 94 Supl. 405a.
27. Le Gac G, Dupradeau F, Mons F, Jacolot S, Scotet V, Esnault G et al. Phenotypic expression of the C282Y/Q283P compound heterozygosity in HFE and molecular modelling of the Q283P mutation effect. Bood Cells Mol Dis 2003; 30: 231-7.
28. Piperno A, Arosio C, Fossati L, Vigano M, Trombini P, Vergani A, Mancia G. Two novel nonsense mutations of HFE gene in five unrelated Italian patients with hemochromatosis. Gastroenterology 2000; 119: 441-5.
29. Pointon JJ, Wallace D, Merryweather-Clarke AT, Robson KJ. Uncommon mutations and polymorphisms in the hemochromatosis gene. Gen Testing 2000; 4: 151-61.
30. Wallace DF, Dooley JS, Walter AP. A novel mutation of HFE explains the classical phenotype of genetic haemochromatosis in a C282Y heterozygote. Gastroenterology 1999; 116: 1409-12.
31. De Marco F, Liguori R, Giardina MG, D'Armiento M, Angelucci E, Lucariello A, et al. High prevalence of non-HFE gene associated haemochromatosis in patients from southern Italy. Clin Chem Lab Med 2004; 42: 17-24.
32. Pardo A, Quintero E, Barrios Y, Bruguera M, Rodrigo L, Vila C, et al. Expresión genotípica y fenotípica de la hemocromatosis hereditaria en España. Gastroenterol Hepatolol 2004; 27: 437-443.
33. Fleming R, Holden C, Tomatsu S, Waheed A, Brunt E, Britton R, et al. Mouse strain differences determine severity of iron accumulation in Hfe knockout model of hereditary hemochromatosis. Proc Natl Acad Sci USA 2001; 98: 2707-11.
34. Bezançon F, De Gennes L, Delarue J, Oumensky D. Cirrhosis pigmentaire avec infantilisme et insuffisance cardiaque et aplasies endocriniennes multiples. Bull Mém Soc Méd Hop Paris 1932; 48: 967-74.
35. Goossens JP. Idiopathic haemochromatosis: Juvenile and familiar type -Endocrine aspects. Neth J Med 1975; 18: 161-9.
36. Lamon JM, Marynick SP, Roseblatt R, Donnelly S. Idiopathic hemochromatosis in a young female. A case study and review of the syndrome in young people. Gastroenterology 1979; 76: 178-83.
37. Kaltwasser JP. Juvenile hemochromatosis. En: Barton JC, Edwards CQ, eds. Hemochromatosis: genetics, pathophysiology, diagnosis, and treatment. Cambridge: Cambridge University Press, 2000. p. 318-28.
38. Varkonyi J, Kaltwasser JP, Seidl C, Kollai G, Andrikovics H, Tordai A. A case of non-HFE juvenile haemochromatosis presenting with adrenocortical insufficiency. Br J Haematol 2000; 109: 252-3.
39. Ross CE, Muir WA, Ng ABP, Graham RC Jr, Kellermeyer RW. Hemochromatosis, pathophysiologic and genetic considerations. Am J Pathol 1975; 63: 179-91.
40. Jensen PD, Baggett J, Jensen FT, Baadrup U, Christensen T, Ellegard J. Heart transplantation in a case of juvenile hereditary hemochromatosis followed up by MRI and endomyocardial biopsies. Eur J Haematol 1993; 51: 199-205.
41. Cazzola M, Cerani P, Rovati A, Iannone A, Claudiani G, Bergamashi G. Juvenile hemochromatosis is clinically and genetically distinct from the classical HLA-related disorder. Blood 1998; 92: 2979-81.
42. Krause A, Neitz S, Magert HJ, Schulz A, Forssmann WG, Schulz-Knappe P, et al. LEAP-1, a novel highly disulfide-bounded human peptide, exhibits antimicrobial activity. FEBS Lett 2000; 480: 147-50.
43. Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 2001; 276: 7811-9.
44. Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002; 110: 1037-44.
45. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003; 101: 2461-3.
46. Courselaud B, Pigeon C, Inoue Y, Gonzalez FJ, Leroyer P, Gilot D, et al. C/EBPα regulates hepatic transcription of hepcidina, an anti-microbial peptide and regulator of iron metabolism. Cross-talk between C/EBP pathway and iron metabolism. J Biol Chem 2002; 277: 41163-70.
47. Leong W, Lönnerdal B. Hepcidin, the recently identified peptide that appears to regulate iron absorption. J Nutr 2004; 134: 1-4.
48. Nicolas G, Bennoun M, Porteu A, Mativet S, Beaumont C, Grandchamp B, et al. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci USA 2002; 99: 4596-601.
49. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003; 102: 783-8.
50. Nicolas G, Bennoun M, Devaux I, Beaumont C, Grandchamp B, Kahn A, et al. Lack of hepcidin gene expression and severe tissue overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci USA 2001; 98: 8780-5.
51. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its intemalization. Science 2004; 306: 2090-3.
52. Weinstein DA, Roy CN, Fleming MD, Loda MF, Wolfsdorf JI, Andrews NC. Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for anaemia of chronic disease. Blood 2002; 100: 3776-81.
53. Roy CN, Weinstein DA, Andrews NC. 2002 E. Mead Johnson Award for Research in Pediatrics Lecture: the molecular biology of the anemia of chronic disease: a hypothesis. Pediatr Res 2003; 53: 507-12.
54. Weiss G. Pathogenesis and treatment of anaemia of chronic disease. Blood Rev 2002; 16: 87-96.
55. Weinstein DA, Roy CN, Fleming MD, Loda MF, Wolfsdorf JI, Andrews NC. Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood 2002; 100: 3776-81.
56. Means RT Jr. The anaemia of infection. Baillieres Best Pract Res Clin Haematol 2002; 13: 151-62.
57. Roetto A, Papanikolaou G, Politou M, et al. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet 2003; 33: 21-2.
58. Roetto A, Daraio F, Porporato P, Caruso R, Cox TM, Cazzola M, et al. Screening hepcidin for mutations in juvenile hemochromatosis: identification of a new mutation (C70R). Blood 2004; 103: 2407-9.
59. Matthes T, Aguilar-Martinez P, Pizzi-Bosman L, Darbellay R, Rubbia-Brandt L, Giosta E, et al. Severe hemochromatosis in a Portuguese family associated with a new mutation in the 5′-URT of the HAMP gene. Blood 2004; 104: 2181-3.
60. Van de Loo JWHP, Creemers JWM, Bright NA, Young BD, Roebroek AJM, Van de Ven WJM. Biosynthesis, distinct post-translational modifications, and functional characterization of lymphoma proprotein convertase. J Biol Chem 1997; 272: 27116-23.
61. Jacolot S, La Gac G, Scotet V, Quere I, Mura C, Ferec C. HAMP as a modifier gene that increases the phenotypic expression of the HFE pC282Y homozygous genotype. Blood 2004; 103: 2835-40.
62. Papanikolaou G, Samuels ME, Ludwig EH, MacDonald MLE, Franchini PL, Dubé MP, et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet 2004; 36: 77-82.
63. Huang FW, Rubio-Aliaga I, Kushner JP, Andrews NC, Fleming MD. Identification of a novel mutation (C321X) in HJV. Blood 2004; 104: 2176-7.
64. Lee PL, Beutler E, Rao SV, Barton JC. Genetic abnormalities and juvenile hemochromatosis: mutations of the HJV gene encoding hemojuvelin. Blood 2004; 103: 4669-71.
65. Lee PL, Barton JC, Brandhagen D, Beutler E. Hemojuvelin (HJV) mutations in persons of European, African-American and Asian ancestry with adults onset haemochromatosis. Br J Haematol 2004; 127: 224-9
66. Lanzara C, Roetto A, Daraio F, Rivard S, Ficarella R, Simard H, et al. Spectrum of hemojuvelin gene mutations in 1q-linked juvenile hemochromatosis. Blood 2004; 103: 4317-21.
67. Barton JC, McDonnell SE, Adams PC, et al. Management of hemochromatosis. Ann Intern Med 1998; 129: 932-9.
68. Nelly AL, Rhodes DA, Roland JM, Schofield P, Cox TM. Hereditary juvenille haemochromatosis: A genetically heterogeneous life-threatening iron-storage disease. Q J Med 1998; 91: 607-18.
69. Cazzola M, Ascari E, Barosi G, Claudiani G, Dacha M, Kaltwasser JP, et al. Juvenile idiopathic hemochromatosis: a life-threatening disorder presenting as hypogonadotropic hypogonadism. Human Genet 1983; 65: 149-54.
70. Case Records of the Massachussets General Hospital. Weekly clinicopathological exercises. Case 31-1994. A 25-year-old man with the recent onset of diabetes mellitus and congestive heart failure. N Engl J Med 1994; 331: 460-6.
71. Camaschella C, Roetto A, Cali A, De Gobbi M, Garozzo G, Carella M, et al. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet 2000; 25: 14-5.
72. Roetto A, Totaro A, Piperno A, Piga A, Longo F, Garozzo G, et al. New mutations inactivating transferring receptor 2 in hemochromatosis type 3. Blood 2001; 97: 2555-60.
73. Girelli D, Bozzini C, Roetto A, Alberti F, Daraio F, Colombari R, et al. Clinical and pathologic findings in hemochromatosis type 3 due to a novel mutation in transferrin receptor 2 gene. Gastroenterology 2002; 122: 1295-302.
74. Pietrangelo A, Caleffi A, Henrion J, Ferrara F, Corradini E, Kulaksiz H, et al. Juvenile hemochromatosis associated with pathogenic mutations of adult hemochromatosis genes. Gastroenterology 2005; 128: 470-9.
75. Hattori A, Wakusawa S, Hayashi H, Harashima A, Sanae F, Kawanaka M, et al. AVAQ 594-597 deletion of the TfR2 gene in a Japanese family with hemochromatosis. Hepatol Res 2003; 26: 154-6.
76. Mattman A, Huntsman D, Lockitch G, Langlois S, Buskard N, Ralston D, et al. Transferrin receptor 2 (TfR2) and HFE mutational análisis in non-C282Y iron overload: identification of a novel TfR2 mutation. Blood 2002; 100: 1075-7.
77. Le Gac G, Mons F, Jacolot S, Scotet V, Férec C, Frébourg T. Early onset hereditary hemochromatosis resulting from a novel TFR2 gene nonsense mutation (R105X) in two siblings of north French descent. Br J Haematol 2004; 125: 674-8.
78. Kawabata H, Yang R, Hirama T, Vuong PT, Kawano S, Gombart AF, et al. Molecular cloning of transferrin 2. A new member of the transferrin receptor-like family. J Biol Chem 1999; 274: 20826-32.
79. Kawabata H, Germain RS, Vuong PT, Nakamaki T, Said JW, Koeffler HP. Transferrin receptor 2-α supports cell growth both in iron-chelated cultured cells and in vivo. J Biol Chem 2000; 275: 16618-25.
80. Kawabata H, Germain RS, Ikezoe T, Tong X, Green EM, Gombart AF, et al. Regulation of expression of murine transferrin receptor 2. Blood 2001; 98: 1949-54.
81. West AP, Bennet MJ, Sellers VM, Andrews NC, Enns CA, Bjorkman PJ, et al. Comparison of the interactions of transferrin receptor and transferrin receptor 2 with transferrin and the hereditary hemocromatosis protein HFE. J Biol Chem 2000; 275: 38135-8.
82. Kawabata H, Nakamaki T, Ikonomi P, Smith RD, Germain RS, Koeffler HP. Expression of transferring 2 in normal and neoplastic hematopoietic cells. Blood 2001; 98: 2714-9.
83. Griffiths WJH, Cox TM. Co-localization of the mammalian hemochromatosis gene product (HFE) and a newly identified transferrin receptor (TfR2) in intestinal tissue and cells. J Histochem Cytochem 2003; 51: 613-23.
84. Richardson DR, Ponka P. The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim Biophys Acta 1997; 1331: 1-40.
85. Piperno A, Roetto A, Mariani R, Pelucchi S, Corengia C, Daraio F, et al. Heterozygosity for transferrin receptor-2 Y250X mutation induces early iron overload. Haematologica 2004; 89: 359-60.
86. Biasiotto G, Belloli S, Ruggeri G, Zanella I, Gerardi G, Corrado M, et al. Identification of new mutations of the HFE, hepcidin, and transferrin receptor 2 genes by denaturing HPLC analysis of individuals with biochemical indications of iron overload. Clin Chem 2003; 49: 1981-8.
87. Fleming RE, Ahmann JR, Migas MC, Waheed A, Koeffler HP, Kawabata H, et al. Targeted mutagenesis of the murine transferrin receptor 2 gene produces hemocromatosis. Proc Natl Acad Sci USA 2002; 99: 10653-8.
88. Eason RJ, Adams PC, Aston CE, Searle J. Familiar iron overload with possible autosomal dominant inheritance. Aust NZ J Med 1990; 20: 226-30.
89. Pietrangelo A, Montosi G, Totaro A, Garuti C, Conte D, et al. Hereditary hemochromatosis in adults without pathogenic mutations in the hemochromatosis gene. N Engl J Med 1999; 341: 725-32.
90. Devalia V, Carter K, Walker AP, Perkins SJ, Worwood M, May A, et al. Autosomal dominat reticuloendothelial iron overload associated with a 3-base pair deletion in the ferroportin 1 gene (SLC11A3). Blood 2002; 100: 695-7.
91. Roetto A, Merryweather-Clarke AT, Daraio F, Livesey K, Pointon JJ, Barbabietola G, et al. A valine deletion of ferroportin 1: a common mutation in hemochromatosis type 4? Blood 2002; 100: 733-4.
92. Jouanolle AM, Douabin-Gicquel V, Halimi C, Loréal O, Fergelot P, Delacour T, et al. Novel mutation in ferroportin 1 gene is associated with autosomal dominant iron overload. J Hepatol 2003; 39: 286-9.
93. Wallace DF, Pedersen P, Dixon JL, Stephenson P, Searle JW, Powell LW, et al. Novel mutation in ferroportin 1 is associated with autosomal dominant hemochromatosis. Blood 2002; 100: 692-4.
94. Arden KE, Wallace DF, Dixon JL, Summerville L, Searle JW, Anderson GJ, et al. A novel mutation in ferroportin 1 is associated with haemochromatosis in a Solomon Islands patient. Gut 2003; 52: 1215-7.
95. Njajou OT, Vaessen N, Joosse M, Gerghnis B, van Dongen JW, Breuning NH, et al. A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis. Nat Genet 2001; 28: 213-4.
96. Montosi G, Donovan A, Totaro A, Garuti C, Pignatti E, Cassanelli S, et al. Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. J Clin Invest 2001; 108: 619-23.
97. Cazzola M, Cremonesi L, Papaioannou M, Soriani N, Kioumi A, Charalambidou A, et al. Genetic hyperferritinaemia and reticuloendothelial iron overload associated with a three base pair deletion in the coding region of the ferroportin gene (SLC11A3). Br J Haematol 2002; 119: 539-46.
98. Donovan A, Brownlie A, Zhou Y, Shepard J, Pratt SJ, Moynihan J, et al. Positional cloning of zebrafish ferroportin 1 identifies a conserved vertebrate iron exporter. Nature 2000; 403: 776-81.
99. Rivard SR, Lanzara C, Grimard D, Carella M, Simard H, Ficarella R, et al. Autosomal dominant reticuloendothelial iron overload (HFE type 4) due to a new missense mutation in the FERROPORTIN 1 gene (SLC11A3) in a large French-Canadian family. Haematologica 2003; 88: 824-5.
100. Hetet G, Devaux I, Soufir N, Grandchamp B, Beaumont C. Molecular analysis of patients with hyperferritinemia and normal serum iron values reveal both L ferritin IRE and 3 new ferroportin (slc11A3) mutations. Blood 2003; 102: 1904-10.
101. Abboud S, Haile DJ. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J Biol Chem 2000; 275: 19906-12.
102. Yang F, Wang X, Haile DJ, Piantadosi CA, Ghio AJ. Iron increases expression of iron-export protein MTP1 in lung cells. Am J Physiol Lung Cell Mol Physiol 2002; 283: 932-9.
103. Martini LA, Tchack L, Wood RJ. Iron treatment downregulates DMT1 and IREG1 mRNA expression in Caco-2 cells. J Nutr 2002; 132: 693-6.
104. Abboud S, Haile DJ. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J Biol Chem 2000; 275: 19906-12.
105. La Vaute T, Smith S, Cooperman S, Iwai K, Land W, Meyron-Holtz E, et al. Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nat Genet 2001; 27: 209-14.
106. Enns CA. Pumping iron: the strange partnership of the hemochromatosis protein, a class I MHC homolog, with the transferrin receptor. Traffic 2001; 2: 167-74.
107. Vulpe CD, Kuo YM, Murphy TL, Cowley L, Askwith C, Libina N, et al. Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse. Nat Genet 1999; 21: 195-9.
108. Pietrangelo A. Non-HFE hemochromatosis. Hepatology 2004; 39: 21-9.
109. Cazzola M. Genetic disorders of iron overload and the novel "ferroportin disease". Haematologica 2003; 88: 721-4.
110. Brittenham GM. The red cell cycle. En: Brock JH, Halliday JW, Pippard MJ, Powell LW, eds. Iron metabolism in health and disease. London, United Kingdom; WB Saunders, 1994. p. 31-62.
111. Heilmeyer L, Keller W, Vivel O, Betker K, Wöhler F, Keiderling W. Die kongenitale Atransferrinämie. Schweiz Med Wochenschr 1961; 91: 1203.
112. Hromec A, Payer J Jr, Killinger Z, Rybar I, Rovensky J. Kongenitale Atransferrinämia. Dtsch Med Wochenschr 1994; 119: 663-6.
113. Goya N, Miyazaki S, Kodate S, Ushio B. A family of congenital atransferrinemia. Blood 1972; 40: 239-45.
114. Loperana L, Dorantes S, Medrano E. Atransferrinemia hereditaria. Bol Med Hosp. Infant Mex 1974; 31: 519.
115. Dorantes-Mesa S, Marquez JL, Valencia-Mayoral P. Sobrecarga de hierro en atranferrinemia hereditaria. Bol Med Hosp. Infant Mex 1986; 43: 99-101.
116. Walbaum R. Déficit congénital en transferrine. Lille Med 1971; 16: 1122-4.
117. Hamill RL, Woods JC, Cook BA. Congenital atransferrinemia: a case report and review of the literature. Am J Clin Pathol 1991; 96: 215-8.
118. Beutler E, Gelbart T, Lee P, Trevino R, Fernandez MA, Fairbanks VF. Molecular characterization of a case of atransferrinemia. Blood 2000; 96: 4071-4.
119. Trenor CC, Campagna DR, Sellers VM, Andrews NC, Fleming MD. The molecular defect in hypotransferinemic mice. Blood 2000; 96: 1113-8.
120. Huggenvik JI, Craven CM, Idzerda RL, Bernstein S, Kaplan J, McKnight GS. A splicing defect in the mouse transferrin gene leads to congenital atransferrinemia. Blood 1989; 74: 482-6.
121. Asasa-Senju M, Maeda T, Sakata T, Hayashi A, Suzuki T. Molecular analysis of the transferrin gene in a patient with hereditary hypotransferrinemia. J Hum Genet 2002; 47: 355-9.
122. Knisely AS, Gelbart T, Beutler E. Molecular characterization of a third case of human atransferrinemia. Blood 2004; 104: 2607.
123. Miyajima H, Nishimura Y, Mizoguchi K, Sakanoto M, Shimizu T, Honda N, et al. Familiar apoceruloplasmin deficiency associated with blepharospasm and retinal degeneration. Neurology 1987; 37: 761-7.
124. Logan JL, Harveyson KB, Wisdom GB, Hughes AE, Archibold GP. Hereditary caeruloplasmin deficiency, dementia and diabetes mellitus. Q J Med 1994; 87: 663-70.
125. Morita H, Ikeda S, Yamamoto K, Morita S, Yoshida K, Nomoto M, et al. Hereditary ceruloplasmin deficiency with hemosiderosis: a clinicopathological study of a Japanese family. Ann Neurol 1995; 37: 646-56.
126. Royle NJ, Irwin DM, Koschinsky ML, MacGillivray RT, Hamerton JL. Human genes encoding prothrombin and ceruloplasmin map to 11p11-q12 and 3q21-24, respectively. Somat Cell MoI Genet 1998; 13: 285-92.
127. Koschinsky ML, Funk WD, Van Oost BA, MacGillivray RT. Complete cDNA sequence of human preceruloplasmin. Proc Natl Acad Sci USA 1986; 83: 5086-90.
128. Harris ZL, Takahashi Y, Miyajima H, Serizawa M, MacGillivray RT. Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. Proc Natl Acad Sci USA. 1995; 92: 2539-43.
129. Yoshida K, Furihata K, Takeda S, Nakamura A, Yamamoto K, Morita H, et al. A mutation in the ceruloplasmin gene is associated with systemic hemosiderosis in humans. Nat Genet 1995; 9: 267-72.
130. Hellman NE, Schaefer M, Gehrke S, Stegen P, Hoffman WJ, Gitlin JD, et al. Hepatic iron overload in aceruloplasminemia. Gut 2000; 47: 858-60.
131. Bosio S, de Gobbi M, Roetto A, Zecchina G, Leonardo E, Rizzetto M, et al. Anemia and iron overload due to compound heterozygosity for novel ceruloplasmin mutations. Blood 2002; 100: 2246-8.
132. Loréal O, Turlin B, Pigeon C, Moisan A, Ropert M, Morice P, et al. Aceruloplasminemia: new clinical, pathophysiological and therapeutic insights. J Hepatol 2002; 36: 851-6.
133. Okamoto N, Wada S, Oga T, Kawabata Y, Baba Y, Habu D, et al. Hereditary ceruloplasmin deficiency with hemosiderosis. Human Genet 1996; 97: 755-8.
134. Morita H, Ikeda S, Yamamoto K, Morita S, Yoshida K, Nomoto S, et al. Hereditary ceruloplasmin deficiency with hemosiderosis: a clinicopathological study of a Japanese family. Ann Neurol 1995; 37: 646-56.
135. Vulpe CD, Kuo YM, Murphy TL, Cowley L, Askwith C, Libina N, et al. Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse. Nat Genet 1999; 21: 195-9.
136. Kaplan J, O'Halloran TV. Iron metabolism in eukaryotes: Mars and Venus at it again. Science 1996; 271: 1510-2.
137. Osaki S, Johnson DEF. The possible significance of the ferrous oxidase activity of ceruloplasmin in normal human serum. J Biol Chem 1996; 241: 2746-51.
138. Yang F, Friedrichs WE, Cupplest RL, Bonifacio MJ, Sanford JA, Horton WA, et al. Human ceruloplasmin. Tissue specific expression of transcripts produced by alternative splicing. J Biol Chem 1990; 285: 10780-5.
139. Ragan HA, Nacht S, Lee GR, Bishop CR, Cartwright GE. Effect of ceruloplasmin on plasma iron in copper-deficient swine. Am J Physiol 1969; 217: 1320-3.
140. Roeser HP, Lee GR, Nacht S, Cartwright GE. The role of ceruloplasmin in iron metabolism. J Clin Invest 1970; 49: 2408-17.
141. Yamamoto K, Yoshida K, Miyagoe Y, Ishikawa A, Hanaoka K, Nomoto S, et al. Quantitative evaluation of expression of iron-metabolism genes in ceruloplasmin-deficient mice. Biochim Biophys Acta 2002; 1588: 195-202.
142. Klomp LWJ, Farhangrazi ZS, Dugan LL, Gitlin JD. Ceruloplamin gene expression in the murine central nervous system. J Clin Invest 1996; 98: 207-15.
143. Kato J, Fujikawa K, Kanda M, Fukuda N, Sasaki K, Takayama T, et al. A mutation, in the iron-responsive element of H ferritin mRNA, causing autosomal dominant iron overload. Am J Hum Genet 2001; 69: 191-7.
144. Beaumont C, Leneuve P, Devaux I, Scoazec JY, Berthier M, Loiseau MN, et al. Mutation of the iron responsive element of the L ferritin mRNA in a family with dominant hyperferritinemia and cataract. Nat Genet 1995; 11: 444-6.
145. Levi S, Girelli D, Perrone F, Pasti M, Beaumont C, Corrocher R, et al. Analysis of ferritins in lymphoblastoid cell lines and in the lens of subjects with hereditary hyperferritinemia-cataract syndrome. Blood; 1998; 91: 4180-7.
146. Ladero JM, Balas A, García-Sánchez F, Vicario JL, Diaz-Rubio M. Hereditary hyperferritinemia-cataract syndrome. Study of a new family in Spain. Rev Esp Enferm Dig 2004; 96: 507-11.
147. Harrison PM, Arosio P. The ferritins: molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta 1996; 1275: 161-203.
148. Ferreira C, Bucchini D, Martin ME, Levi S, Arosio P, Grandchamp B, et al. Early embryonic lethality of H ferritin gene deletion in mice. J Biol Chem 2000; 275: 3021-3.
149. Gordeuk VR. Hereditary and nutritional iron overload. Balliere's Clin Haemat 1992; 5: 169-86.
150. Strachan AS. Haemosiderosis and haemochromatosis in South African natives with a comment on the etiology of haemochromatosis. MD Thesis, University of Glasgow. Scotland, 1929
151. Gordeuk VR, Mukiibi J, Hasstedt SJ, Samowitz W, Edwards CQ, West G, et al. Iron overload in Africa. Interaction between a gene and dietary iron content. N Engl J Med 1992; 326: 95-110.
152. Gordeuk VR, McLaren CE, Looker A, Hasselblad V, Brittenham GM. Distribution of transferrin saturation in the African-American population. Blood 1998; 91: 2175-9.
153. Gangaidzo IT, Moyo VM, Saungweme T, Áhumalo H, Charakupa RM, Gomo ZAR, et al. Iron overload in urban Africans in the 1990s. Gut 1999; 45: 278-83.
154. Bothwell TH, Seftel H, Jacobs P. Iron overload in Bantu subjects. Studies on the availability of iron in Bantu beer. Am J Clin Nutr 1964; 14: 47-51.
155. Moyo VM, Mandishona E, Hasstedt SJ, Gangaidzo IT, Gomo ZA, Khumalo H, et al. Evidence of genetic transmission in African iron overload. Blood 1998; 91: 1076-82.
156. Brink B, Disler P, Lynch S, Jacobs P, Charlton R, Bothwell T, et al. Patterns of iron storage in dietary iron in idiopathic hemochromatosis. J Lab Clin Med 1976; 88: 727-31.
157. Bothwell TH, Abrahams C, Bradlow BA. Idiopathic and Bantu haemochromatosis: comparative histological study. Arch Pathol 1965; 79: 163-8.
158. Gordeuk VR, Caleffi A, Corradine E, Ferrera F, Jones RA, Castro O et al. Iron overload in Africans and African-Americans and a common mutation in the scl40al (ferroportin 1) gene. Blood Cell Mol Dis 2003; 31: 299-304.